Other SMARCA4-deficient malignant tumors (with pi approval)

Clinical trials for Other SMARCA4-deficient malignant tumors (with pi approval) explained in plain language.

Never miss a new study

Get alerted when new Other SMARCA4-deficient malignant tumors (with pi approval) trials appear

Sign up with your email to follow new studies for Other SMARCA4-deficient malignant tumors (with pi approval), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Immunotherapy combo shows promise for rare childhood tumors

Disease control Ongoing

This phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…

Matched conditions: OTHER SMARCA4-DEFICIENT MALIGNANT TUMORS (WITH PI APPROVAL)

Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control

Last updated Jul 03, 2026 00:00 UTC

Other SMARCA4-deficient malignant tumors (with pi approval)

Get alerted when new Other SMARCA4-deficient malignant tumors (with pi approval) trials appear

Immunotherapy combo shows promise for rare childhood tumors